AAAAAA

   
Results: 1-14 |
Results: 14
INTERFERON TREATMENT FOR MULTIPLE-SCLEROSIS - AUTOIMMUNE COMPLICATIONS MAY BE LETHAL
Authors: DURELLI L BONGIOANNI MR FERRERO B OGGERO A MARZANO A RIZZETTO M
Citation: L. Durelli et al., INTERFERON TREATMENT FOR MULTIPLE-SCLEROSIS - AUTOIMMUNE COMPLICATIONS MAY BE LETHAL, Neurology, 50(2), 1998, pp. 570-571
CORTICOSTEROID-INDUCED WORSENING OF MYASTHENIA-GRAVIS (MG) CORRELATESWITH INCREASED IN-VIVO ANTIACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY (AB) LEVEL AND IN-VITRO IMMUNOGLOBULIN (IG) G-RELEASE
Authors: FERRERO B BONGIOANNI MR MOIA MC OGGERO A GEUNA M PAGNI R DURELLI L
Citation: B. Ferrero et al., CORTICOSTEROID-INDUCED WORSENING OF MYASTHENIA-GRAVIS (MG) CORRELATESWITH INCREASED IN-VIVO ANTIACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY (AB) LEVEL AND IN-VITRO IMMUNOGLOBULIN (IG) G-RELEASE, Neurology, 48(3), 1997, pp. 1006-1006
THYROID AND LIVER AUTOIMMUNITY DURING INTERFERON (IFN) TREATMENT FOR MULTIPLE-SCLEROSIS (MS) MAY BE AT TIMES LETHAL
Authors: OGGERO A BONGIOANNI MR MARZANO A AIMO G GENTILE E RIZZETTO M DURELLI L
Citation: A. Oggero et al., THYROID AND LIVER AUTOIMMUNITY DURING INTERFERON (IFN) TREATMENT FOR MULTIPLE-SCLEROSIS (MS) MAY BE AT TIMES LETHAL, Neurology, 48(3), 1997, pp. 4075-4075
AUTOIMMUNE SIDE-EFFECT PROFILE DURING CHRONIC INTERFERON (IFN) THERAPY FOR MULTIPLE-SCLEROSIS (MS)
Authors: DURELLI L SARACCO G RIZZETTO M PAGNI R VERDUN E BONGIOANNI MR BERGAMASCO B
Citation: L. Durelli et al., AUTOIMMUNE SIDE-EFFECT PROFILE DURING CHRONIC INTERFERON (IFN) THERAPY FOR MULTIPLE-SCLEROSIS (MS), Neurology, 48(3), 1997, pp. 4076-4076
MODIFIED AND IMPROVED ANTIACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY-ASSAY - COMPARISON OF ANALYTICAL AND CLINICAL-PERFORMANCE WITH CONVENTIONAL ANTI-ACHR ANTIBODY-ASSAY
Authors: FERRERO B AIMO G PAGNI R BERGAMASCO B BONGIOANNI MR BERGAMINI L DURELLI L
Citation: B. Ferrero et al., MODIFIED AND IMPROVED ANTIACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY-ASSAY - COMPARISON OF ANALYTICAL AND CLINICAL-PERFORMANCE WITH CONVENTIONAL ANTI-ACHR ANTIBODY-ASSAY, Clinical chemistry, 43(5), 1997, pp. 824-831
INTERFERON ALPHA-2A TREATMENT OF RELAPSING-REMITTING MULTIPLE-SCLEROSIS - DISEASE-ACTIVITY RESUMES AFTER STOPPING TREATMENT
Authors: DURELLI L BONGIOANNI MR FERRERO B FERRI R IMPERIALE D BRADAC GB BERGUI M GEUNA M BERGAMINI L BERGAMASCO B
Citation: L. Durelli et al., INTERFERON ALPHA-2A TREATMENT OF RELAPSING-REMITTING MULTIPLE-SCLEROSIS - DISEASE-ACTIVITY RESUMES AFTER STOPPING TREATMENT, Neurology, 47(1), 1996, pp. 123-129
SYSTEMIC HIGH-DOSE RECOMBINANT-ALPHA-2A-INTERFERON THERAPY MODULATES LYMPHOKINE PRODUCTION IN MULTIPLE-SCLEROSIS
Authors: BONGIOANNI MR DURELLI L FERRERO B IMPERIALE D OGGERO A VERDUN E AIMO G PAGNI R GEUNA M BERGAMASCO B
Citation: Mr. Bongioanni et al., SYSTEMIC HIGH-DOSE RECOMBINANT-ALPHA-2A-INTERFERON THERAPY MODULATES LYMPHOKINE PRODUCTION IN MULTIPLE-SCLEROSIS, Journal of the neurological sciences, 143(1-2), 1996, pp. 91-99
CHRONIC ALFA INTERFERON (IFNA) TREATMENT FOR MULTIPLE-SCLEROSIS (MS) MODULATES CYTOKINE PRODUCTION RATHER THAN ANTIGEN PRESENTATION PROCESS
Authors: DURELLI L BONGIOANNI MR FERRERO B VERDUN E RIVA A GUENA M BRADAC GB BERGAMASCO B BERGAMINI L
Citation: L. Durelli et al., CHRONIC ALFA INTERFERON (IFNA) TREATMENT FOR MULTIPLE-SCLEROSIS (MS) MODULATES CYTOKINE PRODUCTION RATHER THAN ANTIGEN PRESENTATION PROCESS, Neurology, 45(4), 1995, pp. 234-234
DECREASED ANTIACETYLCHOLINE RECEPTOR ANTIBODY (ACHR AB) BINDING AVIDITY AFTER HIGH-DOSE GAMMA-GLOBULIN (HIG) CORRELATES WITH CLINICAL EFFICACY IN MYASTHENIA-GRAVIS (MG)
Authors: FERRERO B DURELLI L BONGIOANNI MR AIMO G VERDUN E BERGAMASCO B
Citation: B. Ferrero et al., DECREASED ANTIACETYLCHOLINE RECEPTOR ANTIBODY (ACHR AB) BINDING AVIDITY AFTER HIGH-DOSE GAMMA-GLOBULIN (HIG) CORRELATES WITH CLINICAL EFFICACY IN MYASTHENIA-GRAVIS (MG), Neurology, 45(4), 1995, pp. 283-284
HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) PREVENTS CORTICOSTEROID (ST)-INDUCED WORSENING OF MYASTHENIA-GRAVIS (MG)
Authors: FERRERO B AIMO G DURELLI L CAVALLO R FERRI R BONGIOANNI MR BERGAMASCO B
Citation: B. Ferrero et al., HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) PREVENTS CORTICOSTEROID (ST)-INDUCED WORSENING OF MYASTHENIA-GRAVIS (MG), Neurology, 44(4), 1994, pp. 10000290-10000290
INTERFERON (IFN)-ALPHA(2A) TREATMENT OF RELAPSING REMITTING (R/R) MULTIPLE-SCLEROSIS (MS) - DISEASE-ACTIVITY RESUMES AFTER STOPPING TREATMENT/
Authors: DURELLI L BONGIOANNI MR FERRI R CAVALLO R AIMO G FERRERO B RIVA A BRADAC GB BERGAMASCO B BERGAMINI L
Citation: L. Durelli et al., INTERFERON (IFN)-ALPHA(2A) TREATMENT OF RELAPSING REMITTING (R/R) MULTIPLE-SCLEROSIS (MS) - DISEASE-ACTIVITY RESUMES AFTER STOPPING TREATMENT/, Neurology, 44(4), 1994, pp. 10000358-10000358
CHRONIC SYSTEMIC HIGH-DOSE RECOMBINANT INTERFERON ALFA-2A REDUCES EXACERBATION RATE, MRI SIGNS OF DISEASE-ACTIVITY, AND LYMPHOCYTE INTERFERON-GAMMA PRODUCTION IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS
Authors: DURELLI L BONGIOANNI MR CAVALLO R FERRERO B FERRI R FERRIO MF BRADAC GB RIVA A VAI S GEUNA M BERGAMINI L BERGAMASCO B
Citation: L. Durelli et al., CHRONIC SYSTEMIC HIGH-DOSE RECOMBINANT INTERFERON ALFA-2A REDUCES EXACERBATION RATE, MRI SIGNS OF DISEASE-ACTIVITY, AND LYMPHOCYTE INTERFERON-GAMMA PRODUCTION IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS, Neurology, 44(3), 1994, pp. 406-413
CHRONIC SYSTEMIC RECOMBINANT-ALPHA-2A-INTERFERON (R-ALPHA(2A)-IFN) INHIBITS LYMPHOCYTE GAMMA-IFN PRODUCTION IN MS
Authors: BONGIOANNI MR FERRIO MF FERRERO B VAI S GEUNA M DURELLI L
Citation: Mr. Bongioanni et al., CHRONIC SYSTEMIC RECOMBINANT-ALPHA-2A-INTERFERON (R-ALPHA(2A)-IFN) INHIBITS LYMPHOCYTE GAMMA-IFN PRODUCTION IN MS, Neurology, 43(4), 1993, pp. 164-164
DOES AN ACUTE INCREASE OF ANTIACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY (AB) TITER CONTRIBUTE TO CORTICOSTEROID (ST)-INDUCED WORSENING OF MG
Authors: DURELLI L CAVALLO R FERRERO B BONGIOANNI MR DUTTO A PECCHIO F BERGAMASCO B
Citation: L. Durelli et al., DOES AN ACUTE INCREASE OF ANTIACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY (AB) TITER CONTRIBUTE TO CORTICOSTEROID (ST)-INDUCED WORSENING OF MG, Neurology, 43(4), 1993, pp. 165-165
Risultati: 1-14 |